NEW YORK, Dec. 13 — Q3DM will collaborate with the Genomics Institute of the Novartis Research Foundation in order to develop multiple assays on its high-throughput microscopy platform, the company said Thursday.
The company and the institute will jointly develop a suite of applications for high-throughput cell-based screening, and develop for commercialization a set of assays, reagents, and software products.
Researchers at the Novartis facility will use the technology to improve their cellular genomics discovery program, said institute director Peter Schultz in a statement. The Genomics Institute, which is funded by the Novartis Research Foundation, focuses on applying functional genomics technologies to immunology, cancer, neuroscience, and virology.
Q3DM is a privately held San Diego, Calif., company that provides high-throughput microscopy platforms and optimized assays. Its core technologies include software and hardware for cellular image analysis, image data management, and fluorescence light source stabilization.